Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 3
555
about 3.6 years
12–100
36 sites in AL, AZ, CA +15
About this study
This trial is testing a treatment called remibrutinib compared to placebo in adults with moderate to severe hidradenitis suppurativa. The goal is to see if this treatment is effective, safe, and well-tolerated.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo 1
- 2.Take Placebo 2
- 3.Take Remibrutinib Dose A
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Tablet)
Secondary: Incidence of treatment emergent adverse events and serious adverse events during the study, Percentage change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16, Proportion of participants with clinical response in HS related skin pain (NRS 30), at worst at Week 16